The content on this site is intended for healthcare professionals only
Prof Geetu Bhandoria speaks to ecancer in an online interview for the virtual BGICC 2021 meeting about ERAS in gynaecological oncology, from developed to developing countries.
He explains the background to ERAS pathways, how they have been developed and highlights how there has been a low adoption in their use in developing countries.
Prof Bhandoria believes that the utilisation of the ERAS pathways would be majorly beneficial to developing countries due to its adoption resulting in a reduced cost.
Gaza's cancer patients: Navigating the dual struggle of illness and war
Cancer in emergencies: What can we do better to protect the most vulnerable?
Grand Rounds: Improving quality of patient-centred care
Synthetic biology and precision medicine in blood and gynaecological cancers
Neoadjuvant cemiplimab shows favourable event-free, disease-free and overall survival rates in patients with resectable CSCC
Short-course radiation as effective as standard treatment for breast cancer patients choosing reconstruction after mastectomy
OncoAlert Round Up for September 15-21, 2023
Advancing breast cancer diagnosis in the developing world
Systemic anti-cancer performance matrix
